tradingkey.logo

Merck Says Welireg Plus Lenvima Reduces Risk Of Disease Progression By 30%

ReutersFeb 28, 2026 3:04 PM

- Merck & Co Inc MRK.N:

  • WELIREG® (BELZUTIFAN) PLUS LENVIMA® (LENVATINIB) REDUCED THE RISK OF DISEASE PROGRESSION OR DEATH BY 30% COMPARED TO CABOZANTINIB IN CERTAIN PREVIOUSLY TREATED PATIENTS WITH ADVANCED RENAL CELL CARCINOMA (RCC)

  • MERCK & CO INC - WELIREG PLUS LENVIMA REDUCES RISK OF DISEASE PROGRESSION BY 30%

  • MERCK & CO INC - WELIREG PLUS LENVIMA SHOWS SIGNIFICANT IMPROVEMENT IN PROGRESSION-FREE SURVIVAL

  • MERCK & CO INC - FDA ACCEPTS REVIEW OF TWO SUPPLEMENTAL NDAS FOR WELIREG PLUS LENVIMA

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI